M2I-1
CAS No. 312271-03-7
M2I-1( Mad2 inhibitor 1 )
Catalog No. M13998 CAS No. 312271-03-7
The first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 36 | In Stock |
|
| 5MG | 32 | In Stock |
|
| 10MG | 50 | In Stock |
|
| 25MG | 107 | In Stock |
|
| 50MG | 166 | In Stock |
|
| 100MG | 277 | In Stock |
|
| 200MG | 403 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameM2I-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionThe first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2.
-
DescriptionThe first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2; disturbs conformational dynamics of Mad2 critical for complex formation with Cdc20, weakens the spindle assembly checkpoint (SAC) response.
-
In VitroM2I-1 may not be sufficiently potent to fully inhibit SAC function in cells.M2I-1 weakens the SAC response, indicating that the compound might be active in cells..
-
In Vivo——
-
SynonymsMad2 inhibitor 1
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorOthers
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number312271-03-7
-
Formula Weight404.4832
-
Molecular FormulaC19H24N4O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESO=C(/C(C(N1)=O)=C\C2=CC=C(N(CC(C)C)CC(C)C)C([N+]([O-])=O)=C2)NC1=S
-
Chemical Name4,6(1H,5H)-Pyrimidinedione, 5-[[4-[bis(2-methylpropyl)amino]-3-nitrophenyl]methylene]dihydro-2-thioxo-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kastl J, et al. ACS Chem Biol. 2015 Jul 17;10(7):1661-6.
molnova catalog
related products
-
BQU57
BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth.
-
NU-6300
NU-6300 is the first covalent, irreversible, ATP-Competitive CDK2 inhibitor with Ki of 6 nM.
-
Olomoucine
A potent, ATP-competetive CDKs inhibitor with IC50 of 7, 7, 7, 3 uM for Cdc2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, and Cdk/p35 kinase; also inhibits ERK1/MAP kinase (IC50=25 uM).
Cart
sales@molnova.com